{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:26:59Z","timestamp":1722889619336},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T00:00:00Z","timestamp":1441411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10096-015-2476-9","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T07:28:25Z","timestamp":1441438105000},"page":"2247-2255","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain"],"prefix":"10.1007","volume":"34","author":[{"name":"on behalf of Grupo para el Estudio de las Hepatitis V\u00edricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rivero-Juarez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gutierrez-Valencia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Casta\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"R\u00edos-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Lopez-Ruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Jim\u00e9nez-Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gomez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Hernandez-Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tellez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fernandez-Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,5]]},"reference":[{"key":"2476_CR1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R et al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"2476_CR2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM et al (2014) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384:1597\u20131605","journal-title":"Lancet"},{"key":"2476_CR3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370:1993\u20132001","journal-title":"N Engl J Med"},{"key":"2476_CR4","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J et al (2014) ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370:1983\u20131992","journal-title":"N Engl J Med"},{"key":"2476_CR5","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"2476_CR6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","volume":"385","author":"A Kohli","year":"2015","unstructured":"Kohli A, Osinusi A, Sims Z et al (2015) Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385:1107\u20131113","journal-title":"Lancet"},{"key":"2476_CR7","unstructured":"Recommendations for Testing, Managing, and Treating Hepatitis C of the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA). Available online at: http:\/\/www.hcvguidelines.org . Accessed 21st July 2015"},{"key":"2476_CR8","unstructured":"European Association for the Study of the Liver (EASL) Recommendations on Treatment of Hepatitis C 2014. Available online at: http:\/\/www.easl.eu\/discover\/news\/easl-recommendations-on-treatment-of-hepatitis-c-2014 . Accessed 21st July 2015"},{"key":"2476_CR9","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"2476_CR10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jis927","volume":"207","author":"AY Kim","year":"2013","unstructured":"Kim AY, Onofrey S, Church DR (2013) An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. J Infect Dis 207(Suppl 1):S1\u2013S6","journal-title":"J Infect Dis"},{"key":"2476_CR11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10096-002-0823-0","volume":"21","author":"J Mac\u00edas","year":"2002","unstructured":"Mac\u00edas J, Melguizo I, Fern\u00e1ndez-Rivera FJ et al (2002) Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 21:775\u2013781","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2476_CR12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","volume":"20","author":"N Merchante","year":"2006","unstructured":"Merchante N, Gir\u00f3n-Gonz\u00e1lez JA, Gonz\u00e1lez-Serrano M et al (2006) Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20:49\u201357","journal-title":"AIDS"},{"key":"2476_CR13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.21757","volume":"46","author":"JA Pineda","year":"2007","unstructured":"Pineda JA, Garc\u00eda-Garc\u00eda JA, Aguilar-Guisado M et al (2007) Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46:622\u2013630","journal-title":"Hepatology"},{"key":"2476_CR14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAI.0b013e31815d2f59","volume":"47","author":"C Smit","year":"2008","unstructured":"Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M (2008) Risk of hepatitis-related mortality increased among hepatitis C virus\/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 47:221\u2013225","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2476_CR15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1186\/1471-2334-13-382","volume":"13","author":"V Hernando","year":"2013","unstructured":"Hernando V, Alejos B, Monge S et al (2013) All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997\u20132010. BMC Infect Dis 13:382","journal-title":"BMC Infect Dis"},{"key":"2476_CR16","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/QAD.0b013e3283574e94","volume":"26","author":"J Berenguer","year":"2012","unstructured":"Berenguer J, Alejos B, Hernando V et al (2012) Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 26:2241\u20132246","journal-title":"AIDS"},{"key":"2476_CR17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2012.06.010","volume":"57","author":"V Hernando","year":"2012","unstructured":"Hernando V, Perez-Cachafeiro S, Lewden C et al (2012) All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 57:743\u2013751","journal-title":"J Hepatol"},{"key":"2476_CR18","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/cid\/cit537","volume":"57","author":"J Mac\u00edas","year":"2013","unstructured":"Mac\u00edas J, M\u00e1rquez M, T\u00e9llez F et al (2013) Risk of liver decompensation among HIV\/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy. Clin Infect Dis 57:1401\u20131408","journal-title":"Clin Infect Dis"},{"key":"2476_CR19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A et al (2015) Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:77\u201387","journal-title":"Hepatology"},{"key":"2476_CR20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2007.07.033","volume":"48","author":"JI Esteban","year":"2008","unstructured":"Esteban JI, Sauleda S, Quer J (2008) The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48:148\u2013162","journal-title":"J Hepatol"},{"key":"2476_CR21","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1086\/499960","volume":"42","author":"BR Edlin","year":"2006","unstructured":"Edlin BR, Carden MR (2006) Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 42:673\u2013676","journal-title":"Clin Infect Dis"},{"key":"2476_CR22","doi-asserted-by":"crossref","first-page":"e55373","DOI":"10.1371\/journal.pone.0055373","volume":"8","author":"A Davies","year":"2013","unstructured":"Davies A, Singh KP, Shubber Z et al (2013) Treatment outcomes of treatment-na\u00efve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. PLoS One 8:e55373","journal-title":"PLoS One"},{"key":"2476_CR23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.26741","volume":"59","author":"MA Konerman","year":"2014","unstructured":"Konerman MA, Mehta SH, Sutcliffe CG et al (2014) Fibrosis progression in human immunodeficiency virus\/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 59:767\u2013775","journal-title":"Hepatology"},{"key":"2476_CR24","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1086\/605676","volume":"49","author":"JA Pineda","year":"2009","unstructured":"Pineda JA, Aguilar-Guisado M, Rivero A et al (2009) Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 49:1274\u20131282","journal-title":"Clin Infect Dis"},{"key":"2476_CR25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","volume":"312","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Naggie S, Lalezari J et al (2014) Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA 312:353\u2013361","journal-title":"JAMA"},{"key":"2476_CR26","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","volume":"313","author":"MS Sulkowski","year":"2015","unstructured":"Sulkowski MS, Eron JJ, Wyles D et al (2015) Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 313:1223\u20131231","journal-title":"JAMA"},{"key":"2476_CR27","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jama.2015.1373","volume":"313","author":"A Osinusi","year":"2015","unstructured":"Osinusi A, Townsend K, Kohli A et al (2015) Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 313:1232\u20131239","journal-title":"JAMA"},{"key":"2476_CR28","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/cit103","volume":"56","author":"JA Mira","year":"2013","unstructured":"Mira JA, Rivero-Ju\u00e1rez A, L\u00f3pez-Cort\u00e9s LF et al (2013) Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV\/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis 56:1646\u20131653","journal-title":"Clin Infect Dis"},{"key":"2476_CR29","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ et al (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:2584\u20132593","journal-title":"JAMA"},{"key":"2476_CR30","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12646","volume":"39","author":"J Ampuero","year":"2014","unstructured":"Ampuero J, Romero-G\u00f3mez M, Reddy KR (2014) Review article: HCV genotype 3\u2014the new treatment challenge. Aliment Pharmacol Ther 39:686\u2013698","journal-title":"Aliment Pharmacol Ther"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2476-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-015-2476-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2476-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:05:27Z","timestamp":1553612727000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-015-2476-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,5]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["2476"],"URL":"https:\/\/doi.org\/10.1007\/s10096-015-2476-9","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2015,9,5]]}}}